Bolt Biotherapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Bolt Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $41. The average 1-year stock price forecast is 984.66% higher than the current stock price, while the lowest is $7.00 (+85.19%) and the highest is $75 (+1,884.13%).

Price Target: $41 (+984.66%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.00	$41	$41	$75
Change	+85.19%	+984.66%	+984.66%	+1884.1%

* Price targets were last updated on May 28, 2026.

Analyst Ratings

The average analyst rating for Bolt Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Mar '26	Apr '26	May '26
Strong Buy	1	1	2	2	2	2
Buy	0	1	0	0	0	0
Hold	3	3	3	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	3	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Boris Peaker JonesTrading	JonesTrading	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jun 25, 2026
Michael King Rodman & Renshaw	Rodman & Renshaw	Buy Initiates $22	Buy	Initiates	$22	+482.01%	May 28, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $7	Buy	Reiterates	$7	+85.19%	May 28, 2026
Chad Messer Lake Street	Lake Street	Buy Maintains $75	Buy	Maintains	$75	+1,884.13%	May 13, 2026

Financial Forecast

Revenue This Year

1.51M

from 7.70M

-80.39%

from 7.70M

Revenue Next Year

3.50M

from 1.51M

131.99%

from 1.51M

EPS This Year

-238.28

from -17.06

EPS Next Year

-254.96

from -238.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.26M	5.73M	7.88M	7.69M	7.70M	1.51M
Revenue Growth	445.46%	354.68%	37.48%	-2.36%	0.07%	-80.39%
Operating Income	-92.79M	-90.32M	-76.20M	-68.24M	-34.63M	-45.15M
Net Income	-98.59M	-88.10M	-69.20M	-63.12M	-33.38M	-44.52M
EPS	-	-	-	-	-17.06	-238.28
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	4.5M
Avg	1.5M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-41.2%
Avg	-80.4%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-238.28
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-